Mortality News and Research

RSS

Link between SARS-CoV-2 organotropism and kidney injury

It was clear at a relatively early stage of the pandemic that SARS-CoV-2 causes a wide range of symptoms; in addition to typical respiratory symptoms, patients also had neurological symptoms (starting with anosmia), gastrointestinal symptoms, elevated liver values, and renal, urinary or hematological changes, for example.

8 Jun 2021

Reduced use of convalescent plasma associated with higher COVID-19 mortality rate

A new study from researchers at Johns Hopkins Bloomberg School of Public Health and colleagues suggests a slowdown in the use of convalescent plasma to treat hospitalized COVID-19 patients led to a higher COVID-19 mortality during a critical period during this past winter's surge.

8 Jun 2021

Using AI to fight COVID-19

A study based in Taiwan and published in the Journal of Clinical Medicine focuses on the role of AI in managing COVID-19 through digital images, clinical and laboratory analysis such as screening and diagnosis.

7 Jun 2021

Addressing climate change for better kidney health

Health has always been affected by climate and weather, but is increasingly clear that the change in climate is a significant threat to human health.

7 Jun 2021

Study reports safety, efficacy of targeted treatment for IgA nephropathy

IgA nephropathy (IgAN) is a chronic kidney disease occurring in young adults and is one of the most common reasons for kidney transplantation in this age group.

7 Jun 2021

New research identifies protein as therapeutic anti-viral target for COVID-19

New research identified a novel interaction between the SARS-CoV-2 spike protein and the galectin-3-binding protein (LGALS3BP) which could be a new therapeutic anti-viral target.

7 Jun 2021

Ultrasound examinations can be deployed to detect and treat lung congestion in hemodialysis patients

Accumulation of water in the lungs (lungcongestion) is a common condition in hemodialysis patients, particularly in those at high cardiovascular risk, like those presenting coronary artery disease and/or heart failure.

7 Jun 2021

COVID-19 can cause long-term consequences for the kidneys

The kidneys are a target organ of COVID-19 and are affected very early in the course. However, this is precisely where there is strong prognostic potential: As early as last spring, COVID-19-associated nephritis was identified as an early warning signal for severe courses of the infectious disease and studies to that effect were published.

7 Jun 2021

Majority of women do not meet criteria for cervical cancer screening exit

Current guidelines recommend stopping cervical cancer screening at age 65, but women over age 65 make up over one in five new cervical cancer diagnoses, and are twice as likely to die after a cervical cancer diagnosis compared to younger women.

7 Jun 2021

Repeated low-dose dose exposure to SARS-CoV-2 may protect against severe COVID-19

The Italian authors of this paper, published in the journal Viruses, have taken this hypothesis and expanded it to include viral particles suspended in the air or on inanimate objects as a possible source of T cell immunity due to the repeated low-dose exposure, potentially explaining virus immunity found in non-infected individuals.

7 Jun 2021

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).

7 Jun 2021

New report highlights enormous disease burden and treatment gap of osteoporosis in Europe

New International Osteoporosis Foundation report provides unique overview of osteoporosis in Europe, revealing the enormous disease burden and an unacceptable treatment gap; 71% of women at high risk of fracture are not receiving much-needed medication.

7 Jun 2021

Study offers overview of SARS-CoV-2 infection in children

A new study by researchers in the USA summarizes what is known about the prevalence of the infection, the viral load and transmissibility in children.

7 Jun 2021

The great promise of antiviral peptides against SARS-CoV-2

A new study, recently published in the journal Viruses, describes the impressive evidence for the role of antimicrobial peptidse (AMPs) in the treatment of COVID-19.

7 Jun 2021

Trying to avoid racist health care, Black women seek out Black obstetricians

In South Florida, when people want to find a Black physician, they often contact Adrienne Hibbert through her website, Black Doctors of South Florida.

7 Jun 2021

Patients hospitalized with active cancer are more likely to die from COVID-19

New research indicates that patients hospitalized with active cancer were more likely to die from COVID-19 than those with a history of cancer or those without any cancer diagnosis.

7 Jun 2021

Study suggests prolonged, strict restrictions did not necessarily reduce COVID-19 mortality

A multi-national team of researchers compared COVID-19-related data from different countries in order to better understand the various factors leading to the different results across the world. The multi-disciplinary team included data scientists, software developers, and an infectious diseases physician.

7 Jun 2021

High baseline levels of inflammatory cytokines linked to thrombotic events in patients with COVID-19

In a recent open-access paper published in the Journal of Clinical Medicine, researchers from Iran and Germany show that high baseline levels of inflammatory cytokines measured during admission put patients with coronavirus disease (COVID-19) at increased risk of developing coagulopathy, thrombotic events – and even death.

6 Jun 2021

Standardizable assay detects T cell responses to SARS-CoV-2 infection

Researchers in the UK have developed a high-throughput standardizable assay that accurately detects T cell responses to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

6 Jun 2021

Weight loss drug Wegovy approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.

4 Jun 2021